Search Results - "Sasiela, Bill" :: K.UTB vyhledávací portál

ADVERSE EVENTS IN PATIENTS WITH LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS <25 OR <15 MG/DL ON AT LEAST TWO CONSECUTIVE VISITS IN FOURTEEN RANDOMIZED, CONTROLLED, CLINICAL TRIALS OF ALIROCUMAB

by Robinson, Jennifer, Farnier, Michel, Chaudhari, Umesh, Sasiela, Bill, Lorenzato, Christelle, Miller, Kathryn, Kastelein, John J P
Published in Journal of the American College of Cardiology (17.03.2015)

Get full text

Journal Article

Loading…

A RANDOMIZED STUDY OF THE RELATIVE BIOAVAILABILITY, PHARMACODYNAMICS, AND SAFETY OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, AFTER SINGLE SUBCUTANEOUS ADMINISTRATION AT THREE DIFFERENT INJECTION SITES IN HEALTHY SUBJECTS

by Lunven, Catherine, Paehler, Tobias, Lewanczyk, Pascale, Poitiers, Franck, Brunet, Aurelie, Rey, Jacques, Hanotin, Corinne, Sasiela, Bill
Published in Journal of the American College of Cardiology (01.04.2014)

Get full text

Journal Article

Loading…

RANDOMIZED, PARTIAL BLIND STUDY OF THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF MULTIPLE SUBCUTANEOUS DOSES OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ADMINISTERED EVERY 4 WEEKS ALONE OR IN COMBINATION WITH EZETIMIBE OR FENOFIBRATE IN HEALTHY SUBJECTS

by Rey, Jacques, Poitiers, Franck, Paehler, Tobias, Brunet, Aurelie, Pinquier, Jean-Louis, Hanotin, Corinne, Sasiela, Bill
Published in Journal of the American College of Cardiology (2014)

Get full text

Journal Article

Loading…

RANDOMIZED, PARTIAL BLIND STUDY OF THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF MULTIPLE SUBCUTANEOUS DOSES OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ADMINISTERED EVERY 4 WEEKS ALONE OR IN COMBINATION WITH EZETIMIBE OR FENOFIBRATE IN HEALTHY SUBJECTS

by Rey, Jacques, Poitiers, Franck, Paehler, Tobias, Brunet, Aurelie, Pinquier, Jean-Louis, Hanotin, Corinne, Sasiela, Bill
Published in Journal of the American College of Cardiology (01.04.2014)

Get full text

Journal Article

Loading…

Treat to Target Efficacy of Troglitazone Added to Insulin in Type 2 Diabetes Patients in Endocrine and Primary Care Practice Settings

by HIRSCH, IRL B, SASIELA, BILL, THOMPSON, ROBERT G, MAGGS, DAVID G
Published in Diabetes (New York, N.Y.) (01.05.2000)

Get full text

Journal Article

ADVERSE EVENTS IN PATIENTS WITH LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS <25 OR <15 MG/DL ON AT LEAST TWO CONSECUTIVE VISITS IN FOURTEEN RANDOMIZED, CONTROLLED, CLINICAL TRIALS OF ALIROCUMAB

A RANDOMIZED STUDY OF THE RELATIVE BIOAVAILABILITY, PHARMACODYNAMICS, AND SAFETY OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, AFTER SINGLE SUBCUTANEOUS ADMINISTRATION AT THREE DIFFERENT INJECTION SITES IN HEALTHY SUBJECTS

Treat to Target Efficacy of Troglitazone Added to Insulin in Type 2 Diabetes Patients in Endocrine and Primary Care Practice Settings

Refine Results

Format

Subject Area

Topic

Language

Year of Publication

Database